Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues
You may also be interested in...
Bristol-Myers Squibb board member James Robinson will take on additional corporate governance oversight responsibilities, including meeting with execs prior to analyst calls, as the newly-appointed chairman
Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market
Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level